Rodionov A P, Lyskovtsev V V, Ignatova N A, Tolmacheva E A, Grigor'eva E K, Belinskiaia G F, Sheĭnberg B V
Farmakol Toksikol. 1990 May-Jun;53(3):40-3.
The pharmacokinetics and pharmacodynamics of bonnecor were studied simultaneously in animals with experimental arrhythmia. It was shown that irrespective of the animal species and individual features of the drug elimination kinetics the level of bonnecor concentration correlated with the antiarrhythmic effect. The data on the excretion of bonnecor and its metabolites in the urine in the dog and man were obtained. The decrease of bioavailability at oral administration of bonnecor was demonstrated to be related to its intensive conversion in metabolite M-I.
在患有实验性心律失常的动物中同时研究了博内科尔的药代动力学和药效学。结果表明，无论动物种类以及药物消除动力学的个体特征如何，博内科尔的浓度水平与抗心律失常作用相关。获得了博内科尔及其代谢产物在犬和人尿液中的排泄数据。已证明口服博内科尔时生物利用度的降低与其在代谢产物M-I中的大量转化有关。
